Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II randomized double-blind placebo-controlled study of recombinant botulinum toxin type A injection for masseter prominence in adults
CTR20262283Phase 2Active
- Sponsor
- Ruoyi Biotech
- Start
- Jun 2026
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of JHM03 in masseter hypertrophy, sponsored by Ruoyi Biotech. Started Jun 2026; status: active.
02
Drugs
JHM03
03
Conditions
masseter hypertrophy
Beyond the preview
Go deeper on CTR20262283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262283.